Compare Bristol-Myers Squibb Co (BMY) vs CarMax, Inc (KMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs CarMax, Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.67 (market cap $129.94B), while CarMax, Inc trades at $58.5 (market cap $8.26B). The key difference: Bristol-Myers Squibb Co is far larger — about 15.7× CarMax, Inc's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while CarMax, Inc pays none. Which is the better fit depends on your goals.
| BMY | KMX | |
|---|---|---|
Market Cap | $129.94B | $8.26B |
Sector | Health | Consumer Cyclical |
52-Week High | $65.89 | $62.17 |
52-Week Low | $42.60 | $30.88 |
Enterprise Value | $163.92B | $26.77B |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
CarMax (KMX) trades at $58.705, down 0.13% on the day, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, missing in Q2 2025 but beating in Q3 2025 and Q1 2026, with net income of $500.56M in 2025. Recent news includes a Zacks Strong Buy rating and a partnership with Sierra to enhance customer service, though ongoing legal investigations pose a headwind.
The stock's outlook is cautiously optimistic, supported by improving cash flow trends and analyst buy ratings, but risks include high debt levels and margin pressures. With a consensus price target of $53.09 below the current price, near-term upside may be limited despite positive momentum indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →
